Abstract: A method for removing contaminants from an aqueous solution is provided. The method includes contacting the aqueous solution with steam-activated carbon nanoparticles obtained from oil fly ash and/or date palm fronds under conditions sufficient to adsorb contaminants to the carbon nanoparticles, wherein the carbon nanoparticles are formed into pellets or coated on a fabric sheet. Fabric sheets coated with the carbon nanoparticles are also provided.

Abstract: A method for removing contaminants from an aqueous solution is provided. The method includes contacting the aqueous solution with steam-activated carbon nanoparticles obtained from oil fly ash and/or date palm fronds under conditions sufficient to adsorb contaminants to the carbon nanoparticles, wherein the carbon nanoparticles are formed into pellets or coated on a fabric sheet. Fabric sheets coated with the carbon nanoparticles are also provided.

Abstract: An antimicrobial air treatment device and a method of its construction. The antimicrobial air treatment device comprises an antimicrobial metal nanoparticle mesh comprising a steel support mesh and a layer of copper nanoparticles disposed on the steel support mesh. The antimicrobial air treatment device may be in the form of a facemask or a component of a moving air filtration system such as an HVAC system, an automobile cabin air filtration system, and an air purifier. The antimicrobial air treatment device may contain one or more filtration layers of filtration medium. The method of constructing the antimicrobial air treatment device involves the preparation of the antimicrobial metal nanoparticle mesh by an electrodeposition technique.

Abstract: The present application relates to crystalline and amorphous Vilazodone hydrochloride. The present application further relates to amorphous solid dispersions of vilazodone hydrochloride with pharmaceutically acceptable carriers. The present application also relates to a process for the preparation of form I of vilazodone free base.

Abstract: The present application relates to crystalline and amorphous Vilazodone hydrochloride. The present application further relates to amorphous solid dispersions of vilazodone hydrochloride with pharmaceutically acceptable carriers. The present application also relates to a process for the preparation of form I of vilazodone free base.

Abstract: The present application relates to crystalline and amorphous Vilazodone hydrochloride. The present application further relates to amorphous solid dispersions of vilazodone hydrochloride with pharmaceutically acceptable carriers. The present application also relates to a process for the preparation of form I of vilazodone free base.

Abstract: A torsional damper according to the present disclosure includes an inner sleeve and an outer sleeve. The inner sleeve is configured to couple with a shaft, arranged concentrically with an axis of rotation. The inner sleeve has a generally annular profile with a periphery and a male spline extending from the periphery. The outer sleeve is disposed about the inner sleeve, and arranged concentrically with the inner sleeve. The outer sleeve has a generally annular profile with a periphery and a female spline recessed within the periphery. The inner and outer sleeves are arranged with the male spline disposed within the female spline. The damper additionally includes a resilient coupler arranged between the male spline and the female spline. The damper further includes a ball disposed between the inner sleeve and the outer sleeve and configured to inhibit radial motion of the outer sleeve relative to the inner sleeve.

Abstract: A novel processes for the preparation of suvorexant (formula I), its related compounds and its intermediates that are simple, economical and commercially viable.

Abstract: The present application provide processes for the preparation of fingolimod and its pharmaceutically acceptable salts, process for the purification of fingolimod hydrochloride and process for the preparation of amorphous fingolimod hydrochloride.

Abstract: Provided are crystalline and amorphous vilazodone hydrochloride. Further provided are amorphous solid dispersions of vilazodone hydrochloride with pharmaceutically acceptable carries. Also provided is a process for the preparation of form I of vilazodone free base.

Abstract: A vehicle differential unit (DU), including: a torsional damper assembly having a plurality of independently sprung damper assemblies positioned with respect to the DU, each damper assembly configured to reduce noise or vibration generated by the DU in a predetermined frequency range.

Abstract: A vehicle differential unit (DU), including: a torsional damper assembly having a plurality of independently sprung damper assemblies positioned with respect to the DU, each damper assembly configured to reduce noise or vibration generated by the DU in a predetermined frequency range.

Abstract: The present application provide processes for the preparation of fingolimod and its pharmaceutically acceptable salts, process for the purification of fingolimod hydrochloride and process for the preparation of amorphous fingolimod hydrochloride.

Abstract: The present application provides novel thiazole derivatives that are useful as activators of Adenosine 5?-Monophosphate-Activated Protein Kinase and pharmaceutical compositions containing such compounds.

Abstract: In accordance with one aspect, the present invention provides a compound of general formula (I), its stereoisomers thereof and/or its pharmaceutically acceptable salts thereof, which have antibacterial activity; with methods of treating infectious diseases in warm blooded animals employing these new compounds. wherein R1 is selected from optionally substituted alkyl.

Abstract: The present invention relates to novel propionic acid derivatives. More particularly, the present invention relates to beta-phenyl alpha-oxysubstituted propionic acids of the general formula (I). The present invention also relates to processes for the preparation of compounds of the formula (I) and their use in the preparation of compounds of formula (II).

Abstract: The present invention relates to novel oxazolidinone compounds of formula (I) with antibacterial activity, their pharmaceutically acceptable salts, their stereoisomers, their prodrugs, pharmaceutical compositions comprising the same and to their use as therapeutic agents

Abstract: The present invention is directed to a compounds, methods and compositions for making the compounds and methods of treating a variety of diseases and disease states including atherosclerosis, arthritis, restenosis, diabetic nephropathy, or dyslipidemia, or disease states mediated by the low expression of Perlecan, comprising the administration of new heterocyclic compounds, particularly substituted pyrimidines.

Abstract: The present invention provides new heterocyclic compounds, particularly substituted pyridines, methods and compositions for making and using these heterocyclic compounds, and methods for treating a variety of diseases and disease states, including atherosclerosis, arthritis, restenosis, diabetic nephropathy, or dyslipidemia, or disease states mediated by the low expression of Perlecan.

Abstract: The present invention relates to novel antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic compounds of formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them.